Literature DB >> 19558313

Could strontium ranelate have a synergistic role in the treatment of osteoporosis?

Glen M Blake1, Juliet E Compston, Ignac Fogelman.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19558313     DOI： 10.1359/jbmr.090601

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN： 0884-0431            Impact factor:   6.741


× No keyword cloud information.
  15 in total

Review 1.  The use of combination therapy in the treatment of postmenopausal osteoporosis.

Authors:  Juliet Compston
Journal:  Endocrine       Date:  2011-10-29       Impact factor: 3.633

Review 2.  Nitrile-containing pharmaceuticals: efficacious roles of the nitrile pharmacophore.

Authors:  Fraser F Fleming; Lihua Yao; P C Ravikumar; Lee Funk; Brian C Shook
Journal:  J Med Chem       Date:  2010-08-30       Impact factor: 7.446

3.  Should we really compare absolute risk reduction in different trials on osteoporosis: comment on the article by Ringe JD and Doherty JG.

Authors:  Zhanna E Belaya
Journal:  Rheumatol Int       Date:  2010-12-03       Impact factor: 2.631

4.  A meta-analysis of the effect of strontium ranelate on the risk of vertebral and non-vertebral fracture in postmenopausal osteoporosis and the interaction with FRAX(®).

Authors:  J A Kanis; H Johansson; A Oden; E V McCloskey
Journal:  Osteoporos Int       Date:  2011-02-02       Impact factor: 4.507

5.  Histomorphometric interpretation of bone biopsies for the evaluation of osteoporosis treatment.

Authors:  Juliet E Compston
Journal:  Bonekey Rep       Date:  2012-04-04

6.  Bone: Strontium ranelate does not have an anabolic effect on bone.

Authors:  Glen M Blake; Ignac Fogelman
Journal:  Nat Rev Endocrinol       Date:  2013-10-22       Impact factor: 43.330

7.  The effect of PTH(1-84) or strontium ranelate on bone formation markers in postmenopausal women with primary osteoporosis: results of a randomized, open-label clinical trial.

Authors:  J M Quesada-Gómez; C Muschitz; J Gómez-Reino; H Greisen; H S Andersen; H P Dimai
Journal:  Osteoporos Int       Date:  2010-10-30       Impact factor: 4.507

8.  Strontium ranelate decreases the incidence of new caudal vertebral fractures in a growing mouse model with spontaneous fractures by improving bone microarchitecture.

Authors:  V Geoffroy; D Chappard; C Marty; H Libouban; A Ostertag; A Lalande; M-C de Vernejoul
Journal:  Osteoporos Int       Date:  2010-03-04       Impact factor: 4.507

9.  Zoledronic acid enhances bone-implant osseointegration more than alendronate and strontium ranelate in ovariectomized rats.

Authors:  B Chen; Y Li; X Yang; H Xu; D Xie
Journal:  Osteoporos Int       Date:  2013-02-07       Impact factor: 4.507

Review 10.  Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards.

Authors:  S Vasikaran; R Eastell; O Bruyère; A J Foldes; P Garnero; A Griesmacher; M McClung; H A Morris; S Silverman; T Trenti; D A Wahl; C Cooper; J A Kanis
Journal:  Osteoporos Int       Date:  2010-12-24       Impact factor: 4.507
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.